manufacturing partner?, page-2

I wonder who they are talking about here;

"Matching an off-the-shelf product to a patient is an important step toward consistency and cost reduction, Hei says. "Cost is a huge issue," since developing a unique line of cells for a single patient can cost $30,000 or more. "It's obviously important to drive the price down, that's a key to making this mainstream, affordable health care."

and this;

"Just like drugs, stem cells for clinical trials must be produced under a demanding regulatory regime called "good manufacturing practice," he says. That capacity is rare in labs in private business and universities, and this is the only one at UW–Madison."


The picture is becoming clearer.